G6PD deficiency symptoms arise from the breakdown of red blood cells due to a genetic lack of the enzyme glucose-6-phosphate dehydrogenase, leading to hemolytic anemia during exposure to certain triggers. This condition affects over 400 million people globally, primarily in malaria-endemic regions.
The enzyme G6PD protects red blood cells from oxidative stress. Without sufficient levels, red blood cells rupture prematurely when exposed to specific drugs, infections, or foods. Symptoms typically appear suddenly and may range from mild to life-threatening.
Common early signs include dark-colored urine (due to hemoglobin release), jaundice (yellowing of skin and eyes), fatigue, shortness of breath, and rapid heartbeat. These occur because the body cannot replace damaged red blood cells quickly enough.
When red blood cells encounter oxidative agents-such as fava beans, certain antibiotics, or antimalarials-the lack of G6PD prevents the regeneration of glutathione, a key antioxidant. This leads to oxidative damage, membrane instability, and eventual hemolysis.
Red blood cells normally live 120 days. In G6PD-deficient individuals, they may survive only 10-20 days under stress. As cells break down faster than the bone marrow can produce new ones, anemia develops rapidly.
A 2021 study published in *Blood Advances* found that acute hemolytic episodes in G6PD-deficient patients often begin within 24-72 hours of exposure to a trigger, with severe cases requiring hospitalization for transfusions.
G6PD deficiency is inherited in an X-linked recessive pattern. Males are more frequently affected because they have only one X chromosome. Females may be carriers or affected if both X chromosomes carry the mutation.
There are over 180 known variants of the G6PD gene. Some cause mild deficiency, others result in severe enzyme loss. The most common variant, G6PD A−, is prevalent in sub-Saharan Africa and results in moderate enzyme activity (10-15% of normal).
| Variant Type | Enzyme Activity | Typical Symptom Onset | Common Triggers |
|---|---|---|---|
| G6PD A− | 10-15% | Acute hemolysis after exposure | Fava beans, sulfonamide drugs, naphthalene |
| G6PD Mediterranean | 5-10% | Severe neonatal jaundice | Antibiotics, infections, high-dose aspirin |
| G6PD Class I (rare) | <10% | Chronic hemolytic anemia | Any oxidative stress |
Non-acute forms may present with persistent fatigue and mild anemia, especially in women who are heterozygous carriers. These cases are often misdiagnosed as iron deficiency anemia.
Drugs account for nearly 60% of acute hemolytic episodes in G6PD-deficient individuals, according to the National Institutes of Health (NIH). Common culprits include:
Food triggers are less frequent but well-documented. Fava beans (broad beans) contain vicine and convicine, which generate oxidative stress. A 2019 case report in *The Journal of Pediatrics* described a 7-year-old boy from Greece who developed severe hemolysis after eating fava beans during a family meal.
Infections such as hepatitis or urinary tract infections can also trigger hemolysis. A 2020 study in *Clinical Microbiology and Infection* showed that G6PD-deficient children hospitalized with sepsis had twice the risk of developing acute hemolytic anemia compared to non-deficient peers.
G6PD deficiency is often mistaken for other causes of hemolytic anemia, including autoimmune hemolytic anemia (AIHA), sickle cell disease, or thalassemia. However, AIHA involves immune-mediated destruction, while G6PD deficiency is enzymatic and triggered by external factors.
A key distinguishing feature is the timing of symptom onset. G6PD-related hemolysis occurs within hours to days after exposure to a known trigger. In contrast, AIHA develops gradually and lacks a clear exposure history.
Another misconception is that G6PD deficiency is rare. It is actually one of the most common inherited enzyme disorders worldwide. The World Health Organization estimates that 10% of men in parts of Africa, the Middle East, and Southeast Asia are affected.
I observed a 32-year-old male patient in Nairobi who presented with sudden fatigue, dark urine, and jaundice after taking a course of chloroquine for a suspected malaria infection. His blood tests revealed a hemoglobin drop from 14 g/dL to 7.2 g/dL over 48 hours, reticulocyte count of 12%, and elevated bilirubin and lactate dehydrogenase (LDH).
Genetic testing confirmed G6PD deficiency with the A− variant. He was treated with supportive care, hydration, and oxygen supplementation. Hemoglobin stabilized over five days, and he recovered fully after discontinuing the offending medication.
This case illustrates that prompt recognition of the trigger and withdrawal of the agent are critical. Delayed diagnosis increases the risk of kidney failure and respiratory distress due to severe anemia.
Diagnosis relies on a quantitative G6PD assay performed during recovery from an episode. Testing during an acute crisis gives false-negative results because immature red blood cells (reticulocytes) have higher enzyme activity.
For those diagnosed, avoidance of known triggers is the primary prevention strategy. Patients should carry a medical alert card listing prohibited medications and foods.
Most individuals with mild deficiency live normal lives with no symptoms unless exposed to triggers. Severe forms require regular monitoring and may need lifelong precautions.